Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.960 -0.170 (-1.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
News headline image
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit ↗
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from  
Via Benzinga
News headline image
Stocks Edge Higher As End Of 2023 Approaches ↗
The SPX is less than 10 points away from record close territory, and with one day left, all three major indexes are heading toward sizable December wins. 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a... 
Via Benzinga
Topics Intellectual Property Lawsuit Stocks
News headline image
7 Analysts Have This To Say About NeoGenomics ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About NeoGenomics ↗
 
Via Benzinga
News headline image
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
NeoGenomics to Appeal Ruling
Via ACCESSWIRE
News headline image
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
News headline image
Bull Of The Day: NeoGenomics ↗
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
News headline image
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Via ACCESSWIRE
News headline image
Where NeoGenomics Stands With Analysts ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About NeoGenomics ↗
 
Via Benzinga
News headline image
NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat ↗
NeoGenomics, Inc. (NASDAQ: NEO) reported Q2 revenues of $146.92 million, +18% Y/Y, beating the  
Via Benzinga
News headline image
NeoGenomics Reports Second Quarter 2023 Results
Via ACCESSWIRE
News headline image
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Via ACCESSWIRE
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2023 ↗
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. 
Via Benzinga
News headline image
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Via ACCESSWIRE
News headline image
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
News headline image
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
News headline image
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark ↗
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
News headline image
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
News headline image
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
News headline image
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.